Background: Patients with atrial fibrillation (AF) and chronic kidney disease represent a high-risk group for thromboembolism and bleeding. Aims: To explore the relationship between kidney function changes and outcomes of stroke/systemic embolism (SE), major bleeding and all-cause death in anticoagulated AF patients participating in the BOREALIS trial comparing efficacy and safety of once-weekly s.c. idrabiotaparinux to that of warfarin. Methods: Changes in kidney function by estimated glomerular filtration rate (eGFR) were calculated using the Chronic Kidney Disease Epidemiology Collaboration equation in 2765 AF patients. Trial adjudicated outcomes were determined. Results: After a mean follow-up of 394 days, in 94.4% of the included patients kidney function changed ranging from −30 mL/min to 30 mL/min. The incidence of stroke/ SE and major bleeding was similar between patients with deteriorated (reduction in eGFR from baseline over follow-up) and preserved kidney function change (increase or no change in eGFR from baseline over follow-up) [stroke/SE: incidence rate (IR):
| INTRODUC TI ON
Atrial fibrillation (AF) and chronic kidney disease (CKD) often complicate each other 1 and there is evidence that CKD markedly increases the risk of stroke (even with the use of oral anticoagulation), 2 as well as bleeding and mortality in AF patients. 3, 4 Uncertainty exists among specialists on the best use of anticoagulation in AF patients with concomitant CKD. 5 As there are few studies on the relationship between deterioration of kidney function and the adjudicated outcomes of anticoagulation in patients with AF.
We performed a secondary analysis of evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients with Atrial Fibrillation (BOREALIS) trial 6 comparing idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with AF to address the unclear associations between the relative risk of stroke, major bleeding, and mortality with changes in kidney function in AF.
| MATERIAL S AND ME THODS
The design and results of the BOREALIS trial have previously been described and details provided in Supplemental Methods. 6 In brief, the BOREALIS trial was a multicenter randomized trial comparing idrabiotaparinux and dose-adjusted warfarin for the prevention of thromboembolism in patients with nonvalvular AF. 6 The trial protocol was approved by the institutional review board and all patients have provided written informed consent. The trial was stopped early, and showed a comparable effect in stroke and SE prevention of once-weekly s.c. idrabiotaparinux to that of warfarin, but with inconclusive noninferiority because the upper 95% confidence limit of the primary efficacy outcome (stroke/SE,1.66) was above the prespecified margin for noninferiority (1.38) .
To be included in the present analysis: (a) patients should have baseline creatinine measurements; and (b) last creatinine measured within 90 days before the end of the study treatment or after the end of the study treatment. Consequently, patients were divided into two groups according to their kidney function changes, from baseline to the end of the follow-up, calculated using chronic kidney disease epidemiology collaboration (CKD-EPI) equation. Changes in kidney function were categorized as "preserved" (ie, increase or no change in eGFR from baseline over follow-up) or "deteriorated" (reduction in eGFR from baseline over follow-up). The "deteriorated" group included all individuals who had any level of deterioration in kidney function. Those with kidney function deterioration ≥40 mL/ min were defined as abrupt deterioration.
| Estimation of kidney function
Three widely used formulae were used to estimate the kidney functions in each patient, as follows: 
| Study endpoints
In this analysis we included all study outcomes, collected from the baseline to the end of the study. The primary analysis of the BOREALIS trial reported only outcomes collected during the treatment period. 6 The primary efficacy outcome of this analysis was the composite of stroke and systemic embolism (SE). The principal safety outcome of the present analysis was major bleeding, the definition of which was based on the criteria published. 6, 10 All-cause death was also studied in this study. 6, 10 Suspected outcome events were adjudicated by an independent central adjudication committee who were blinded to treatment assignment. 
| Statistical analysis

| RE SULTS
After a follow-up of 394 [208-531] days, 2765 participating AF patients in the BOREALIS trial had both measured creatinine variables at baseline and the end of study treatment. Baseline characteristics were compared between the deteriorated and preserved kidney function change (calculated using CKD-EPI eGFR) groups in AF patients randomized to the two anticoagulant treatment arms ( Table 1) .
Those with deteriorated kidney function change had a tendency to have a higher mean HAS-BLED score and lower kidney function, but other baseline characteristics were not significantly different. 
TA B L E 1 Baseline Characteristics
TA B L E 1 (Continued)
Abrupt kidney function reduction of ≥40 mL/min occurred in 29 patients, which was 1.8% of the deteriorated group.
| Kidney function changes
The distribution of kidney function changes, calculated using three calculation methods and then categorized by 10 unit increments is shown in Figure S1 . Of note, 94.4% (calculated using CKD-EPI eGFR), 
| All-cause deaths
All-cause deaths included 9 strokes, 1 non-CNS systemic embolism, 
| Thromboembolic outcomes according to kidney function changes
The incidence of stroke/SE events was similar between deteriorated (incidence rate (IR) 1.33) and preserved kidney function change (IR 1.80) (hazard ratio (HR): 0.74, 95% confidence interval (CI) 0.41 − 1.32, P = .30) ( Figure S3 ). There were consistent effects with nonsignificant differences between deteriorated and preserved kidney function changes in different settings of DM, HPT, and HF.
Adjusted Cox regression analysis found no effect taking kidney function changes as continuous variables, whether calculated using CKD-EPI, MDRD, or Cockcroft-Gault equations ( 
| Bleeding outcomes according to kidney function changes
The incidence of major bleeding events was similar between preserved (IR 1.63%/year) and deteriorated (IR 1.49%/year) kidney function changes in the whole group (HR: 1.10, 95% CI: 0.61-1.97, P = .76).
Consistency in bleeding risk was also seen in subgroups including DM, HPT, and HF. There were no significant associations between the changes in kidney function, calculated using the three estimation methods, and the risk of major bleeding ( Table 2) . A separate Cox model, adjusted for the baseline kidney function, did not show an association with the risk of major bleeding (HR: 0.99, 95% CI: 0.97-1.01, P = .26).
Patients with a deteriorated change in kidney function were at higher risk for all-cause death (HR: 1.64, 95% CI: 1.02-2.63, P = .04), particularly in those complicated with hypertension (HR: 1.79, 95% CI: 1.07-2.98, P = .03) and heart failure (HR: 1.91, 95% CI: 1.03-3.56, P = .04). The annualized incidence of all-cause death in those with a deteriorated kidney function change was 3.19% per year compared to those with preserved kidney function change, being 1.94% per year ( Figure S3 ).
Cox regression analysis showed negative independent associations between kidney function changes, assessed by all three estimation methods, and all-cause death ( Table 2) . Baseline kidney function, calculated by CKD-EPI eGFR formula, did not show independent association with all-cause death (HR: 1.00, 95% CI: 0.98-1.01, P = .82). As demonstrated in Figure 1 , the incidence rate of all-cause death decreased with improved kidney function during the study treatment period (P < .001). If we restricted the analysis to those patients with mild-moderate changes in kidney function, that is, after excluding those with abrupt changes in kidney function 
| D ISCUSS I ON
In the BOREALIS trial population, the risk of all-cause mortality was significantly higher in anticoagulated AF patients whose kidney function decreased abruptly over the study treatment period.
Stroke/SE, major bleedings, and all-cause death were not related to mild-moderate changes in kidney function (±30 mL/min).
There remains a dilemma balancing stroke/SE and major bleeding when oral anticoagulation is used in patients with concurrent AF and CKD. 11 Patients with AF are also inclined to develop kidney dysfunction. 12, 13 However, no significant difference in the risk of stroke/SE and major bleeding was seen in the present study between deteriorated and preserved kidney function during the anticoagulation treatment period, with similar kidney function change between VKA and idrabiotaparinux. One reason was perhaps the narrow range of kidney function changes from baseline to the end of study treatment, as more than 70% of included patients had kidney function changes (calculated using three formulae) within 15 mL/min (from −15 to 15 mL/min) and more than 90% within 30 mL/min (from −30 to 30 mL/min). Previous meta-analyses 2,3 showed no significant increase in risk of major bleeding and stroke/SE if kidney function deteriorated within 30% of the baseline kidney function, 14, 15 the conclusion of which was further confirmed by our study because of similar kidney function change scope.
In previous studies of AF patients using warfarin for anticoagulation, kidney dysfunction was a risk factor for death. 16 However, no significant differences between baseline kidney function and mortality were found in the study of Marcos et al. 17 In our analysis, we assessed kidney function using three different formulae 
| Limitations
The strength of this analysis is the adjudicated clinical outcomes from the posthoc analysis of this trial cohort, but there are several limitations to be mentioned for this study. First, these posthoc analyses from the BOREALIS trial should be interpreted as hypothesis generating only, especially given the limited statistical power for some smaller subgroups. Second, most of the changes in kidney function ranged from −30 to 30 mL/min, and the majority of AF patients enrolled had relatively stable kidney function. Therefore, the results should be cautiously extrapolated to those patients with sharp changes in kidney (dys)function. Third, the underlying pathogenic mechanism(s) were not explored. Finally, we cannot account for the multiple drug therapy changes (and dose alterations) over the follow-up period.
| CON CLUS IONS
In this trial cohort of anticoagulated AF patients, the risk of allcause death was significantly increased in AF patients showing abruptly deteriorating kidney function. There were no significant effects on the risk of stroke/SE, major bleeding, and all-cause death were seen when kidney function changed from −30 to 30 mL/min.
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